Plasma coagulation and hemostatic system

The plasma coagulation and hemostatic system is a complex physiological network responsible for maintaining vascular integrity and preventing blood loss through the formation of clots at sites of injury (StatPearls, 2023). It involves a series of enzymatic reactions, primarily involving serine proteases known as clotting factors (e.g., Factor VII, IX, X, and Prothrombin), which act in a cascade to ultimately generate thrombin and convert fibrinogen into a stable fibrin mesh (NIH, 2022). This system is tightly regulated by natural anticoagulants like Protein C, Protein S, and Antithrombin to prevent systemic thrombosis while ensuring a rapid localized response (Merck Manual, 2023). Pathological imbalances in this system lead to significant morbidity, including venous thromboembolism, myocardial infarction, and stroke, or conversely, bleeding disorders like hemophilia (StatPearls, 2023). Pharmacological modulation of the hemostatic system is a major therapeutic strategy, utilizing anticoagulants to prevent clot formation, antiplatelets to inhibit primary hemostasis, and thrombolytics to dissolve existing clots (PubMed, 2021). Because it encompasses dozens of distinct proteins and cellular components, it is characterized as a biological system or pathway rather than a single molecular target (NIH, 2022). Therapeutic agents typically target specific components within this system, such as Factor Xa or Thrombin, to achieve precise clinical outcomes (PubMed, 2021).

Other names

Coagulation cascadeBlood clotting systemHemostasisHemostatic pathway

Drugs targeting this system act by inhibiting specific coagulation factors (e.g., Factor Xa, Thrombin), antagonizing Vitamin K-dependent carboxylation, or promoting the degradation of fibrin clots (fibrinolysis).